Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:diseases:hypertension [01.04.2019]
sallieq [Recent research]
home:diseases:hypertension [03.30.2020] (current)
sallieq [Hypertension (high blood pressure)]
Line 6: Line 6:
  
  
 +<​relatedarticle>​ [[home:​protocol:​olmesartan#​other beneficial effects|Science behind Olmesartan, section on cardiovascular_disease]] </​article>​
 ===== Introduction ===== ===== Introduction =====
  
Line 19: Line 20:
 Follow your doctor'​s advice regarding monitoring your blood pressure to determine if your current blood pressure medication/​s are effective. Your blood pressure will come down as your Th1 inflammation resolves and you will need less blood pressure medication and then may no longer need additional B/P medication. Your doctor will advise you on how and when to adjust your blood pressure medication/​s. Follow your doctor'​s advice regarding monitoring your blood pressure to determine if your current blood pressure medication/​s are effective. Your blood pressure will come down as your Th1 inflammation resolves and you will need less blood pressure medication and then may no longer need additional B/P medication. Your doctor will advise you on how and when to adjust your blood pressure medication/​s.
  
-If your B/P is too high, we suggest adding ​a beta blocker, an ACE inhibitor or a calcium channel blocker (in that order of perference) to your ARB (Benicar).+If your B/P is too high, it is possible to add a beta blocker, an ACE inhibitor or a calcium channel blocker (in that order of perference) to your ARB (Benicar).
  
 ==== If your BP rises on the MP ==== ==== If your BP rises on the MP ====
Line 116: Line 117:
 Olmesartan ameliorated arterial stiffness in patients with hypertension,​ which may be involved in the reduction of serum A-FABP. ​  ​(({{pubmed>​long:​21063874}})) Olmesartan ameliorated arterial stiffness in patients with hypertension,​ which may be involved in the reduction of serum A-FABP. ​  ​(({{pubmed>​long:​21063874}}))
  
-Given the involvement of oxidative stress and its signaling in atherogenesis,​ and the available evidence of olmesartan'​s vasoprotective,​ anti-inflammatory and antiatherosclerotic effects derived from clinical trials in humans, the results of our study provide a mechanistic rationale for the omelsartan's antioxidant and anti-inflammatory potential translation,​ in the long term, toward the antiatherosclerotic and antiremodeling effects reported on the clinical ground. ​ (({{pubmed>​long:​21504378}}))+Given the involvement of oxidative stress and its signaling in atherogenesis,​ and the available evidence of olmesartan'​s vasoprotective,​ anti-inflammatory and antiatherosclerotic effects derived from clinical trials in humans, the results of our study provide a mechanistic rationale for the olmesartan's antioxidant and anti-inflammatory potential translation,​ in the long term, toward the antiatherosclerotic and antiremodeling effects reported on the clinical ground. ​ (({{pubmed>​long:​21504378}}))
  
 {{tag>​disease symptoms }} {{tag>​disease symptoms }}
home/diseases/hypertension.1546645642.txt.gz · Last modified: 01.04.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.